During the past decade, Samyang Biopharmaceuticals conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Samyang Biopharmaceuticals" are "Breast Cancer" (1 trials), "Esophageal Cancer" (1 trials), "Gastric Cancer" (1 trials), "Gynecologic Cancer" (1 trials) and "Head and Neck Cancer" (1 trials). Many other conditions were trialed in "Samyang Biopharmaceuticals" in a lesser frequency.

Most popular intervention types in "Samyang Biopharmaceuticals" are "Drug" (3 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Genexol-PM" (2 trials), "Docetaxel-PM" (1 trials), "Gemcitabine" (1 trials), "Marlex® Mesh Implant" (1 trials) and "Proflex® Mesh Mesh implantation" (1 trials). Other intervention names were less common.

The vast majority of trials in "Samyang Biopharmaceuticals" are 3 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Samyang Biopharmaceuticals". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Samyang Biopharmaceuticals, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Samyang Biopharmaceuticals, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".